SMART-102 is under clinical development by Smart Immune and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SMART-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SMART-102 is under development for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is administered through intravenous route. The therapeutic candidate comprises allogenic T cell progenitor cells derived from cord blood. It is developed based on ProTcel platform.
Smart Immune overview
Smart Immune is a company dedicated to the development of T-cell progenitor-based cell and gene therapy to combat blood cancers and infections. Smart Immune is headquartered in Paris, Ile-de-France, France.
For a complete picture of SMART-102’s drug-specific PTSR and LoA scores, buy the report here.